Drug
Ggta1 KO Thymokidney
Ggta1 KO Thymokidney: highest development phase Phase 1/2, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| GGTA1 KO Thymokidney NCT07224763 | Phase 1/2 | ESRD (End-Stage Renal Disease) |
Latest
No recent events.
Follow Ggta1 KO Thymokidney on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.